120 related articles for article (PubMed ID: 3654151)
21. Successful mafosfamide purging of bone marrow from chronic myelogenous leukemia (CML) cells.
Nieborowska-Skórska M; Skórski T; Ratajczak MZ; Szczylik C; Malaguarnera L; Calabretta B
Folia Histochem Cytobiol; 1993; 31(4):161-7. PubMed ID: 8137996
[TBL] [Abstract][Full Text] [Related]
22. Effect of mafosfamide (ASTA-Z-7654) on the clonogenic cells in precursor-B acute lymphoblastic leukaemia: significance for ex vivo purging of bone marrow for autologous transplantation.
Makrynikola V; Kabral A; Bradstock KF
Bone Marrow Transplant; 1991 Nov; 8(5):351-5. PubMed ID: 1768969
[TBL] [Abstract][Full Text] [Related]
23. Observations on the effects of cyclophosphamide, phosphoramide mustard and some activated oxazaphosphorines on murine L1210 leukemia.
Zaharko DS; Covey JM; Hörpel G
Invest New Drugs; 1984; 2(2):149-54. PubMed ID: 6469508
[TBL] [Abstract][Full Text] [Related]
24. Modulation of IL-10/IL-10R expression by mafosfamide, a derivative of 4-hydroxycyclophosphamide, in a rat B-cell lymphoma.
Rico MJ; Matar P; Scharovsky OG
Biocell; 2012 Aug; 36(2):91-5. PubMed ID: 23185784
[TBL] [Abstract][Full Text] [Related]
25. Cyclophosphamide- or ifosfamide-treated L 1210 leukaemia cells: immunogenicity, viability and metabolism.
Skórski T; Kawalec M; Hoser G
Folia Biol (Praha); 1986; 32(5):354-65. PubMed ID: 3506526
[TBL] [Abstract][Full Text] [Related]
26. Successful purging of murine plasmacytoma by mafosfamide (ASTA-Z).
Weiss L; Slavin G; Reich S; Sidi H; Slavin S
Bone Marrow Transplant; 1994 Jan; 13(1):27-30. PubMed ID: 8019450
[TBL] [Abstract][Full Text] [Related]
27. C-myc expression is down-regulated in mafosfamide-treated HL-60 cells undergoing apoptosis.
Davidoff AN; Mendelow BV
Anticancer Res; 1993; 13(4):1167-70. PubMed ID: 8352540
[TBL] [Abstract][Full Text] [Related]
28. In vitro chemosensitivity of leukemic progenitor cells (AML-CFU) to a combination of mafosfamide lysine (ASTA-Z 7654) and etoposide (VP16-213).
Deconinck E; Tamayo E; Hervé P
Bone Marrow Transplant; 1990 Jan; 5(1):13-8. PubMed ID: 2297586
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide.
Uckun FM; Chandan-Langlie M; Dockham PA; Aeppli D; Sladek NE
Leuk Lymphoma; 1994 May; 13(5-6):417-28. PubMed ID: 8069187
[TBL] [Abstract][Full Text] [Related]
30. Antineoplastic activity of ASTA Z 7557 (NSC-345842, INN mafosfamide) on transplantable murine tumors.
Atassi G; Hilgard P; Pohl J
Invest New Drugs; 1984; 2(2):169-73. PubMed ID: 6469511
[TBL] [Abstract][Full Text] [Related]
31. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of cytogenetic damage and of antineoplastic effect in lymphoid L1210 leukemia cells treated with prostaglandin E2 and cyclophosphamide in vivo.
Mourelatos D; Mioglou E; Kristi Z; Dozi-Vassiliades J
Mutat Res; 1995 Jan; 326(1):125-9. PubMed ID: 7528880
[TBL] [Abstract][Full Text] [Related]
33. Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.
Struck RF; Dykes DJ; Corbett TH; Suling WJ; Trader MW
Br J Cancer; 1983 Jan; 47(1):15-26. PubMed ID: 6821629
[TBL] [Abstract][Full Text] [Related]
34. Phase-I study of mafosfamide-cyclohexylamine (ASTA-Z-7557, NSC 345 842) and limited phase-I data on mafosfamide-lysine.
Bruntsch U; Groos G; Hiller TA; Wandt H; Tigges FJ; Gallmeier WM
Invest New Drugs; 1985; 3(3):293-6. PubMed ID: 4066222
[TBL] [Abstract][Full Text] [Related]
35. Pharmacologic bone marrow purging: is there any place for etoposide? In vitro comparison with mafosfamide.
Olivieri A; Poloni A; Montanari M; Cantori I; Corvatta L; Masia MC; Curzi L; Mancini S; Leoni P
J Hematother; 1997 Apr; 6(2):137-44. PubMed ID: 9131443
[TBL] [Abstract][Full Text] [Related]
36. Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials.
Mazur L; Opydo-Chanek M; Stojak M; Wojcieszek K
Anticancer Res; 2012 Jul; 32(7):2783-9. PubMed ID: 22753738
[TBL] [Abstract][Full Text] [Related]
37. Difference in kinetics of hematopoietic reconstitution between ALL and ANLL after autologous bone marrow transplantation with marrow treated in vitro with mafosfamide (ASTA Z 7557).
Douay L; Laporte JP; Mary JY; Lopez M; Lemonnier MP; Stachowiak J; Benitez O; Deloux J; Najman A; Salmon C
Bone Marrow Transplant; 1987 Jun; 2(1):33-43. PubMed ID: 3332155
[TBL] [Abstract][Full Text] [Related]
38. Cellular composition of spleen and peritoneal exudate in mice after injection of cyclophosphamide-treated L 1210 leukemia cells.
Skórski T; Kawalec M; Kawiak J
Folia Histochem Cytobiol; 1987; 25(1):23-7. PubMed ID: 3305097
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of cyclophosphamide-treated leukaemia cells.
Kawalec M; Jakóbisiak M; Skórski T; Kawiak J
Folia Biol (Praha); 1982; 28(5):334-43. PubMed ID: 6816636
[TBL] [Abstract][Full Text] [Related]
40. Combination of immunotherapy with cyclophosphamide/actinomycin D chemotherapy potentiates antileukemic effect and reduces toxicity in a L1210 leukemia model in mice.
Lasek W; Sora M; Wańkowicz A; Jakóbisiak M
Cancer Lett; 1995 Feb; 89(1):137-43. PubMed ID: 7882296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
